NEW YORK, Oct. 24-Biogen has renewed and expanded its license for Lexicon Genetics' knockout-based gene targeting technology, Lexicon said today.
The agreement expands upon a deal first struck in September 2000, whereby Biogen secured the rights to use Lexicon's "positive negative selection technology," a method to generate knockout mice useful in validating drug targets.
This license also gives Biogen non-exclusive rights to Lexicon's isogenic DNA gene targeting technology.
Financial details of this agreement were not revealed.
For further details, see the press release.